Risk of blood clots in veins hereditary

Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmo have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by studying the risk of VTE in children of parents with VTE compared with the children of parents who have not had VTE.

"Previously, hereditary factors for have only been studied on a small scale. We based our study on the entire Swedish population", says Bengt Zöller, researcher at the Centre for Research, Malmö. Using the national multi-generation register and hospital discharge register, the researchers examined the risk of being affected if one or both parents have had venous thromboembolism. During the period 1987 to 2007, a total of 45 362 people suffered from venous thromboembolism, of whom 4 865 had hereditary VTE and thus a higher risk of being affected.

The study shows that hereditary factors are of most significance at a younger age ¬– between 10 and 50 – and occur in both men and women. The highest relative risk was seen in the 10-19 age group. After the age of 50, other factors appear to play a greater role than hereditariness. Blood clots in the very young, under the age of 10, are rare, but strangely enough, hereditary factors do not appear to be the most significant in this age group. The highest risk occurs if both parents have had venous thromboembolism.

"The findings are an important guide to the importance of hereditary factors for VTE. In conclusion, a parental history of venous thromboembolism is an important risk factor that should be included in the clinical medical history and examination", says Bengt Zöller.

Provided by Lund University
Citation: Risk of blood clots in veins hereditary (2011, May 31) retrieved 25 April 2024 from https://medicalxpress.com/news/2011-05-blood-clots-veins-hereditary.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Widely used cancer drug associated with significantly increased risk of blood clots

 shares

Feedback to editors